⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
Inizio Unveils Next-Generation Hub Services at Asembia 2026, Setting a New Standard in Patient Access
prnewswire.com
INCY
MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
prnewswire.com
INCY
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight
globenewswire.com
TSEM
TAK
MRK
IONS
SLN
INCY
JNJ
VNDA
Incyte präsentiert neue Phase-3-Daten zu Tafasitamab auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO)
businesswire.com
INCY
Incyte présente de nouvelles données de phase III sur le tafasitamab au congrès annuel 2026 de l’American Society of Clinical Oncology (ASCO)
businesswire.com
INCY
Resumen: Incyte presenta nuevos resultados del estudio clínico en fase 3 de tafasitamab en el Congreso Anual 2026 de la American Society of Clinical Oncology (ASCO)
businesswire.com
INCY
Samenvatting: Incyte licht nieuwe gegevens van tafasitamab Fase 3 toe tijdens de 2026 ASCO (American Society of Clinical Oncology) Annual Meeting
businesswire.com
INCY
インサイト、2026年米国臨床腫瘍学会（ASCO）年次総会でタファシタマブの第3相臨床試験の最新データを発表
businesswire.com
INCY
Riassunto: Incyte evidenzia i nuovi dati su tafasitamab forniti dallo studio di fase 3 al Meeting annuale 2026 della American Society of Clinical Oncology (ASCO)
businesswire.com
INCY
Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight
globenewswire.com
AZN
CRSP
NKTR
INCY
IPHA
ABBV
BIIB
ALKS
IMVT
CLRB
IMPP
REGN
THO
AUTL
KYMR
CBIO
GILD